Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
about
Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementBiochemical alterations during the obese-aging process in female and male monosodium glutamate (MSG)-treated mice.Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome.MicroRNAs-Mediated Regulation of Skeletal Muscle GLUT4 Expression and Translocation in Insulin Resistance.Muscle IGF-1-induced skeletal muscle hypertrophy evokes higher insulin sensitivity and carbohydrate use as preferential energy substrate.Omega-3 Fatty Acids Supplementation Differentially Modulates the SDF-1/CXCR-4 Cell Homing Axis in Hypertensive and Normotensive Rats.Soybean and sunflower oil-induced insulin resistance correlates with impaired GLUT4 protein expression and translocation specifically in white adipose tissue.Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes.Resveratrol Improves Glycemic Control in Type 2 Diabetic Obese Mice by Regulating Glucose Transporter Expression in Skeletal Muscle and Liver.Hepatosteatosis and hepatic insulin resistance are blunted by argirein, an anti-inflammatory agent, through normalizing endoplasmic reticulum stress and apoptosis in diabetic liver.Carbohydrate- and lipid-enriched meals acutely disrupt glycemic homeostasis by inducing transient insulin resistance in rats.Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression.
P2860
Q26783199-64DDDF77-44C9-46C9-AD90-BD806D22E244Q34072214-BAB6ECFE-6842-42CC-9A93-2CE27B0B4221Q35228184-76FFC9FE-E0D3-4524-A952-A52C66C14622Q36104044-7AA13EB5-1FAD-4E55-8B3F-71341CD08F28Q36227874-7B76EF0D-4026-4FB2-A3A4-0920EC1C6486Q37744073-637D1BD3-47BF-4A23-BBFA-52CA1088E322Q41341487-60E4890F-7679-435E-AD11-54B93DB5CBCFQ41583929-0D107B1C-7B34-4D2B-9C16-384F202D45EBQ43189050-A6194895-FD99-44DD-A9E7-6CC29D30463FQ50540691-255D6202-C0B8-4A04-803B-5252F37BAE06Q50891043-E21C4AEB-D35C-4766-84B0-CFDB8ED2F51BQ51016955-2E87AB1C-8CCE-436C-8E7A-A5C4EC307523Q51358108-E83762C6-2DDC-48DF-8B69-BF3A38AF2E34Q54986288-0745B2DB-834A-416F-99BE-15766807FB34
P2860
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@en
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@nl
type
label
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@en
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@nl
prefLabel
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@en
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
@nl
P2093
P2860
P1476
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin
@en
P2093
A E Hirata
M M Okamoto
R C T Mori
U F Machado
P2860
P304
P356
10.1111/J.1463-1326.2008.00870.X
P577
2008-03-18T00:00:00Z